미용치료용 엔디-야그레이저에 의한 황반병증에서 항혈관내피성장인자항체로 치료한 1예

• Published in: 검안 및 콘택트렌즈 학회지, 20(3) pp. 119 - 123
• Main Authors: 마건정, 박선경, 김미리내, 박영근, 박영훈, 김래영
• Format: Journal Article
• Language: Korean
• Published: 대한검안학회 30.09.2021
• Subjects: 안과학
• ISSN: 2384-0919; 2384-0927

Purpose: To report a follow up of early intravitreal anti-vascular endothelial growth factor (VEGF) antibody treatment in a patient with maculopathy after accidental exposure to a high-powered cosmetic Nd:YAG laser. Case summary: A 36-year-old female patient visited our clinic with decreased visual acuity in the right eye after accidental exposure to a high-powered cosmetic Nd:YAG laser. The best-corrected visual acuity of the right eye was 0.1 and subretinal hemorrhage on the foveal area was observed during fundus examination. Optical coherence tomography revealed serous retinal detachment with hyperreflective disruption of the ellipsoid zone and retinal pigment epithelium-Bruch’s membrane complex. Intravitreal bevacizumab (Avastin® , 1.25 mg/0.05 mL; Roche Korea, Seoul, Korea) injections were performed three times. Visual acuity was unchanged at 6 months after the first visit. However, complete resolution of the subretinal hemorrhage was observed and there were no signs of secondary choroidal neovascularization or recurrence of choroidal hemorrhage. Conclusions: Early anti-VEGF antibody treatment in a patient with subfoveal hemorrhage and choroidal rupture after high-powered cosmetic Nd:YAG laser exposure improved morphology and prevented secondary choroidal neovascularization. KCI Citation Count: 0